Telix Pharmaceuticals Valuation Multiples

Telix Pharmaceuticals Overview

About Telix Pharmaceuticals

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Founded

2017

HQ

Employees

1.2K

Website

telixpharma.com

Sectors

Medical Imaging & DiagnosticsBioTechHealthTech

Financials (LTM)

Revenue: $852M

EBITDA: $48M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Telix Pharmaceuticals Financials

Telix Pharmaceuticals reported last 12-month revenue of $852M and EBITDA of $48M.

In the same LTM period, Telix Pharmaceuticals generated $457M in gross profit, $48M in EBITDA, and had net loss of ($1M).

Telix Pharmaceuticals P&L

In the most recent fiscal year, Telix Pharmaceuticals reported revenue of $804M and EBITDA of $42M.

Telix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals has current market cap of $4B, and enterprise value of $4B.

Telix Pharmaceuticals' stock price is $10.48.

Telix Pharmaceuticals Valuation Multiples

Telix Pharmaceuticals trades at 4.5x EV/Revenue multiple, and 81.2x EV/EBITDA.

Telix Pharmaceuticals Financial Valuation Multiples

As of April 19, 2026, Telix Pharmaceuticals has market cap of $4B and EV of $4B.

Equity research analysts estimate Telix Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Telix Pharmaceuticals has a P/E ratio of (2467.8x).

Telix Pharmaceuticals Margins & Growth Rates

Telix Pharmaceuticals' revenue in the last 12 month grew by 19%.

Telix Pharmaceuticals' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Telix Pharmaceuticals' rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Telix Pharmaceuticals' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Telix Pharmaceuticals Public Comps

See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.

Telix Pharmaceuticals M&A Activity

Telix Pharmaceuticals acquired XXX companies to date.

Last acquisition by Telix Pharmaceuticals was on XXXXXXXX, XXXXX. Telix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Telix Pharmaceuticals Investment Activity

Telix Pharmaceuticals invested in XXX companies to date.

Telix Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Telix Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).